Major Depressive Disorder (MDD)

Major Depressive Disorder (MDD) profoundly impacts the lives of many individuals, particularly those facing suicidal ideation or Treatment-Resistant Depression (TRD). The weight of these severe forms of depression can be overwhelming, but there are innovative solutions available to help reignite hope and foster recovery.

With advancements in treatment options such as Esketamine (Spravato), individuals struggling with MDD now have access to therapies that can provide rapid relief and address the unique challenges posed by persistent depression. These breakthroughs offer a beacon of hope for those who have not found success with traditional methods.

While the treatment journey may seem daunting, understanding and support are crucial. With our commitment to high-quality, compassionate care, individuals can reclaim control over their lives and rediscover joy. Hope is within reach, and a brighter future is possible.

Prevalence

Suicidal ideation is more common in patients with TRD (38.7%) compared to non-TRD patients (24.9%)

Impact on Quality of Life

MDD SI patients show significantly greater adverse impacts on quality of life, more severe.

Physical Pain

There’s a notable association between physical pain and suicidal behavior in depressed patients.

Treatment Challenges

Patients with a history of suicidal ideation or attempts may have more difficulty achieving remission with standard treatments.

Treatment-Resistant Depression (TRD)

Treatment-Resistant Depression is a subset of Major Depressive Disorder that does not respond adequately to at least two different antidepressant treatments of adequate dose and duration

  • Up to 50-60% of patients with MDD may not achieve adequate response following antidepressant treatment.
  • Diagnosis: Requires a thorough re-evaluation, considering factors such as medical and psychiatric comorbidities
  • Staging: Various methods exist to assess levels of treatment resistance, though consensus on a standard definition is lacking
  • Impact: TRD is associated with lower long-term quality of life and higher relapse rates compared to treatment-responsive depression
  • Treatment Options: May include pharmacological augmentation strategies (e.g., lithium, triiodothyronine, second-generation antipsychotics), switching antidepressant classes, and non-pharmacological interventions like Esketamine (Spravato) or repetitive transcranial magnetic stimulation (rTMS)

SCHEDULE A CONSULTATION

REFER A PATIENT

This form is to be completed by the patient, patient’s caregiver or patient’s referring healthcare provider.